Variant "OPRM1:c.1323A>G(p.Gly441Gly)"
Search result: 1 record
Variant information
Gene:
Variant:
OPRM1:c.1323A>G(p.Gly441Gly) 
Genomic location:
chr6:154414563(hg19) 
HGVS:
SO Term RefSeq
protein_coding NM_001008505.2:c.1323A>G(p.Gly441Gly)
protein_coding NM_001008504.3:c.*1941A>G
protein_coding NM_001285523.1:c.*1539A>G
protein_coding NM_001285527.1:c.*1941A>G
protein_coding NM_001285528.1:c.*1539A>G
protein_coding NM_001145279.3:c.1443+1956A>G
protein_coding NM_001145280.3:c.864+1956A>G
protein_coding NM_001145281.2:c.921+1956A>G
protein_coding NM_000914.4:c.1164+1956A>G
protein_coding NM_001285522.1:c.291-25255A>G
protein_coding NM_001285524.1:c.1443+1956A>G
protein_coding NM_001145285.2:c.1164+1956A>G
protein_coding NM_001145286.2:c.1164+1956A>G
protein_coding NM_001145283.2:c.1164+1956A>G
protein_coding NM_001145284.3:c.1164+1956A>G
pseudogene NR_104351.1:n.1299-782A>G
protein_coding NM_001145282.2:c.1164+1956A>G
pseudogene NR_104349.1:n.1299-782A>G
pseudogene NR_104348.1:n.1299-782A>G
pseudogene NR_104350.1:n.945+1956A>G
protein_coding NM_001008503.2:c.1164+1956A>G
protein_coding NM_001145287.2:c.864+1956A>G
protein_coding NM_001285526.1:c.864+1956A>G
show all
dbSNP ID:
GWAS trait:
Modifier statisitcs
Record:
Disorder:
Reference:
Effect type:
Expressivity(1)  
Modifier effect:
Altered onset time(1)  
Detail:
  • Target disease:
    Alzheimer's Disease (DOID_10652)
    Effect type:
    Expressivity 
    Modifier effect:
    Altered onset time 
    Evidence:
    P(FDR)=1.15×10(-33) 
    Effect:
    Genome-wide statistically significant mutations of major modifier effect on the the age of onset (AOO) in Azheimer's disease
    Reference:
    Title:
    Mutations modifying sporadic Alzheimer's disease age of onset.
    Species studied:
    Human
    Abstract:
    The identification of mutations modifying the age of onset (AOO) in Alzheimer's disease (AD) is crucial for understanding the natural history of AD and, therefore, for early interventions. Patients with sporadic AD (sAD) from a genetic isolate in the extremes of the AOO distribution were whole-exome genotyped. Single- and multi-locus linear mixed-effects models were used to identify functional variants modifying AOO. A posteriori enrichment and bioinformatic analyses were applied to evaluate the non-random clustering of the associate variants to physiopathological pathways involved in AD. We identified more than 20 pathogenic, genome-wide statistically significant mutations of major modifier effect on the AOO. These variants are harbored in genes implicated in neuron apoptosis, neurogenesis, inflammatory processes linked to AD, oligodendrocyte differentiation, and memory processes. This set of new genes harboring these mutations could be of importance for prediction, follow-up and eventually as therapeutical targets of AD. 2016 Wiley Periodicals, Inc.